Yao, Sheng

Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.

Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research

Cancer Immunotherapy and BiomarkersPI3K/AKT/mTOR signaling in cancer

Cited by 785

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 175

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Mao, L., Lian, B., Bai, X., Wang, X., et al. (2019) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 169

The midkine family of growth factors: diverse roles in nervous system formation and maintenance

Winkler, C., & Yao, S. (2014) · British Journal of Pharmacology

Nerve injury and regenerationNeurogenesis and neuroplasticity mechanisms

Cited by 72